{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T02:11:49Z","timestamp":1760926309157,"version":"build-2065373602"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Protein Expression and Purification"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.pep.2021.105950","type":"journal-article","created":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T08:17:08Z","timestamp":1628065028000},"page":"105950","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Generation and characterization of a humanized anti-IL-17A rabbit monoclonal antibody"],"prefix":"10.1016","volume":"187","author":[{"given":"Wei","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meijuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiliang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huaiyao","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihua","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiwan","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.pep.2021.105950_bib1","doi-asserted-by":"crossref","first-page":"102429","DOI":"10.1016\/j.autrev.2019.102429","article-title":"Critical role of interleukin (IL)-17 in inflammatory and immune disorders: an updated review of the evidence focusing in controversies","volume":"19","author":"de Morales","year":"2020","journal-title":"Autoimmun. Rev."},{"issue":"2","key":"10.1016\/j.pep.2021.105950_bib2","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.cyto.2013.07.022","article-title":"IL-17 family: cytokines, receptors and signaling","volume":"64","author":"Gu","year":"2013","journal-title":"Cytokine"},{"issue":"2","key":"10.1016\/j.pep.2021.105950_bib3","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.bbrc.2016.06.049","article-title":"IL-17A synergistically enhances TNFalpha-induced IL-6 and CCL20 production in 3T3-L1 adipocytes","volume":"477","author":"Shinjo","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"9","key":"10.1016\/j.pep.2021.105950_bib4","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1056\/NEJMra0707449","article-title":"Interleukin-17 and type 17 helper T cells","volume":"361","author":"Miossec","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.pep.2021.105950_bib5","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.molmed.2016.01.001","article-title":"IL-17 in chronic inflammation: from discovery to targeting","volume":"22","author":"Beringer","year":"2016","journal-title":"Trends Mol. Med."},{"issue":"10","key":"10.1016\/j.pep.2021.105950_bib6","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nrd3794","article-title":"Targeting IL-17 and TH17 cells in chronic inflammation","volume":"11","author":"Miossec","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"issue":"24","key":"10.1016\/j.pep.2021.105950_bib7","doi-asserted-by":"crossref","first-page":"9326","DOI":"10.1074\/jbc.M117.818559","article-title":"A bispecific antibody that targets IL-6 receptor and IL-17A for the potential therapy of patients with autoimmune and inflammatory diseases","volume":"293","author":"Lyman","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.pep.2021.105950_bib8","doi-asserted-by":"crossref","first-page":"111018","DOI":"10.1016\/j.biopha.2020.111018","article-title":"Corrigendum to \"The effects of neutralizing anti-murine interleukin-17A monoclonal antibody on ozone-induced inflammation and glucocorticoids insensitivity in a murine model of asthma\" [Biomed. Pharmacother. 114 (2019) 108786]","volume":"133","author":"Zhang","year":"2021","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.pep.2021.105950_bib9","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1159\/000460514","article-title":"Blocking IL-17A alleviates Diabetic retinopathy in rodents","volume":"41","author":"Qiu","year":"2017","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.pep.2021.105950_bib10","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/9404505","article-title":"Secukinumab-induced inflammatory bowel disease in a patient treated for chronic plaque psoriasis and psoriatic arthritis: a case report and review of the role of novel biologic agents targeting the p19 subunit of IL-23","volume":"2020","author":"Darch","year":"2020","journal-title":"Case. Rep. Med."},{"issue":"8","key":"10.1016\/j.pep.2021.105950_bib11","first-page":"821","article-title":"Secukinumab improves physical function in subjects with plaque psoriasis and psoriatic arthritis: results from two randomized, phase 3 trials","volume":"14","author":"Gottlieb","year":"2015","journal-title":"J. Drugs Dermatol."},{"issue":"11","key":"10.1016\/j.pep.2021.105950_bib12","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1080\/17512433.2016.1242409","article-title":"Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis","volume":"9","author":"Vu","year":"2016","journal-title":"Expet Rev. Clin. Pharmacol."},{"issue":"12","key":"10.1016\/j.pep.2021.105950_bib13","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1093\/rheumatology\/keaa189","article-title":"Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials","volume":"59","author":"Genovese","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.pep.2021.105950_bib14","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1080\/14712598.2020.1776256","article-title":"Brodalumab in the treatment of chronic plaque psoriasis","volume":"20","author":"Gisondi","year":"2020","journal-title":"Expet Opin. Biol. Ther."},{"issue":"3","key":"10.1016\/j.pep.2021.105950_bib15","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1038\/emm.2017.23","article-title":"From rabbit antibody repertoires to rabbit monoclonal antibodies","volume":"49","author":"Weber","year":"2017","journal-title":"Exp. Mol. Med."},{"issue":"9","key":"10.1016\/j.pep.2021.105950_bib16","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jtho.2018.05.013","article-title":"PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project","volume":"13","author":"Tsao","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.pep.2021.105950_bib17","doi-asserted-by":"crossref","first-page":"1814661","DOI":"10.1080\/19420862.2020.1814661","article-title":"Biased anti-idiotype response in rabbits leads to high-affinity monoclonal antibodies to biologics","volume":"12","author":"Gro\u00dferichter-Wagener","year":"2020","journal-title":"MAbs"},{"issue":"1591","key":"10.1016\/j.pep.2021.105950_bib18","first-page":"23","article-title":"Brolucizumab (Beovu) for age-related macular degeneration","volume":"62","year":"2020","journal-title":"Med. Lett. Drugs Ther."},{"issue":"1599","key":"10.1016\/j.pep.2021.105950_bib19","first-page":"85","article-title":"Eptinezumab (Vyepti) for migraine prevention","volume":"62","year":"2020","journal-title":"Med. Lett. Drugs Ther."},{"issue":"2","key":"10.1016\/j.pep.2021.105950_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0009072","article-title":"A humanized anti-VEGF rabbit monoclonal antibody inhibits angiogenesis and blocks tumor growth in xenograft models","volume":"5","author":"Yu","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.pep.2021.105950_bib21","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.3389\/fimmu.2018.01682","article-title":"The IL-17 family of cytokines in psoriasis: IL-17A and beyond","volume":"9","author":"Brembilla","year":"2018","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.pep.2021.105950_bib22","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.immuni.2015.12.003","article-title":"Th17 cell pathway in human immunity: lessons from genetics and therapeutic interventions","volume":"43","author":"Patel","year":"2015","journal-title":"Immunity"},{"issue":"16","key":"10.1016\/j.pep.2021.105950_bib23","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.2174\/1389450117666160307144027","article-title":"IL-17A and multiple sclerosis: signaling pathways, producing cells and target cells in the central nervous system","volume":"17","author":"Kolbinger","year":"2016","journal-title":"Curr. Drug Targets"},{"issue":"9","key":"10.1016\/j.pep.2021.105950_bib24","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/annrheumdis-2019-215356","article-title":"The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies","volume":"78","author":"McGonagle","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.pep.2021.105950_bib25","doi-asserted-by":"crossref","first-page":"104351","DOI":"10.1016\/j.phrs.2019.104351","article-title":"IL-17A neutralizing antibody regulates monosodium urate crystal-induced gouty inflammation","volume":"147","author":"Raucci","year":"2019","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.pep.2021.105950_bib26","doi-asserted-by":"crossref","first-page":"111554","DOI":"10.1016\/j.yexcr.2019.111554","article-title":"IL-17A neutralizing antibody attenuates eosinophilic meningitis caused by Angiostrongylus cantonensis by involving IL-17RA\/Traf6\/NF-kappaB signaling","volume":"384","author":"Feng","year":"2019","journal-title":"Exp. Cell Res."},{"issue":"2","key":"10.1016\/j.pep.2021.105950_bib27","doi-asserted-by":"crossref","first-page":"ii116","DOI":"10.1136\/annrheumdis-2012-202371","article-title":"Effect of IL-17A blockade with secukinumab in autoimmune diseases","volume":"72","author":"Patel","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.pep.2021.105950_bib28","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.2147\/DDDT.S105263","article-title":"Secukinumab for rheumatology: development and its potential place in therapy","volume":"10","author":"Koenders","year":"2016","journal-title":"Drug Des. Dev. Ther."},{"issue":"6","key":"10.1016\/j.pep.2021.105950_bib29","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.ad.2017.02.005","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis: subgroup analysis of Latin American patients in the phase 3 randomized UNCOVER-3 study","volume":"108","author":"Valenzuela","year":"2017","journal-title":"Actas. Dermosifiliogr"},{"issue":"1","key":"10.1016\/j.pep.2021.105950_bib30","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"Mease","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.pep.2021.105950_bib31","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/bcp.13185","article-title":"First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis","volume":"83","author":"Glatt","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.pep.2021.105950_bib32","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s40259-019-00361-6","article-title":"Bimekizumab: the first dual inhibitor of interleukin (IL)-17A and IL-17F for the treatment of psoriatic disease and ankylosing spondylitis","volume":"33","author":"Reis","year":"2019","journal-title":"BioDrugs"},{"key":"10.1016\/j.pep.2021.105950_bib33","first-page":"29","article-title":"Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential","volume":"9","author":"Chiricozzi","year":"2019","journal-title":"Psoriasis (Auckl)."},{"issue":"2","key":"10.1016\/j.pep.2021.105950_bib34","doi-asserted-by":"crossref","first-page":"ii43","DOI":"10.1093\/rheumatology\/kew346","article-title":"Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseases","volume":"55","author":"Nirula","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.pep.2021.105950_bib35","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/bjd.14965","article-title":"Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis","volume":"176","author":"Reich","year":"2017","journal-title":"Br. J. Dermatol."},{"issue":"9","key":"10.1016\/j.pep.2021.105950_bib36","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1111\/jdv.15637","article-title":"Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years","volume":"33","author":"Reich","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"11","key":"10.1016\/j.pep.2021.105950_bib37","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/ajg.2016.298","article-title":"A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn's disease","volume":"111","author":"Targan","year":"2016","journal-title":"Am. J. Gastroenterol."},{"issue":"12","key":"10.1016\/j.pep.2021.105950_bib38","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"A human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"issue":"9999","key":"10.1016\/j.pep.2021.105950_bib39","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"FUTURE 2 Study Group, Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"}],"container-title":["Protein Expression and Purification"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1046592821001339?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1046592821001339?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T01:55:45Z","timestamp":1760925345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1046592821001339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":39,"alternative-id":["S1046592821001339"],"URL":"https:\/\/doi.org\/10.1016\/j.pep.2021.105950","relation":{},"ISSN":["1046-5928"],"issn-type":[{"type":"print","value":"1046-5928"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Generation and characterization of a humanized anti-IL-17A rabbit monoclonal antibody","name":"articletitle","label":"Article Title"},{"value":"Protein Expression and Purification","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pep.2021.105950","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105950"}}